BDTX Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. (BDTX) is expected to report earnings on February 9, 2027, after the market close. The consensus earnings estimate is a loss of $0.21 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -19.5% since its last earnings release on November 10, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics is a precision oncology medicine company pioneering the development of novel MasterKey therapies.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.